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ABSTRACT
OBJECTIVES
To describe neurodevelopmental outcomes at 2 years 
corrected age for children born alive at 22-26, 27-31, 
and 32-34 weeks’ gestation in 2011, and to evaluate 
changes since 1997.
DESIGN
Population based cohort studies, EPIPAGE and 
EPIPAGE-2.
SETTING
FRANCE.
PARTICIPANTS
5567 neonates born alive in 2011 at 22-34 completed 
weeks’ gestation, with 4199 survivors at 2 years 
corrected age included in follow-up. Comparison of 
outcomes reported for 3334 (1997) and 2418 (2011) 
neonates born alive in the nine regions participating 
in both studies.
MAIN OUTCOME MEASURES
Survival; cerebral palsy (2000 European consensus 
definition); scores below threshold on the 
neurodevelopmental Ages and Stages Questionnaire 
(ASQ; at least one of five domains below threshold) 
if completed between 22 and 26 months corrected 
age, in children without cerebral palsy, blindness, or 
deafness; and survival without severe or moderate 
neuromotor or sensory disabilities (cerebral palsy with 
Gross Motor Function Classification System levels 2-5, 
unilateral or bilateral blindness or deafness). Results 
are given as percentage of outcome measures with 
95% confidence intervals.
RESULTS
Among 5170 liveborn neonates with parental consent, 
survival at 2 years corrected age was 51.7% (95% 
confidence interval 48.6% to 54.7%) at 22-26 weeks’ 
gestation, 93.1% (92.1% to 94.0%) at 27-31 weeks’ 
gestation, and 98.6% (97.8% to 99.2%) at 32-34 
weeks’ gestation. Only one infant born at 22-23 weeks 
survived. Data on cerebral palsy were available for 
3599 infants (81.0% of the eligible population). The 
overall rate of cerebral palsy at 24-26, 27-31, and 
32-34 weeks’ gestation was 6.9% (4.7% to 9.6%), 
4.3% (3.5% to 5.2%), and 1.0% (0.5% to 1.9%), 
respectively. Responses to the ASQ were analysed 
for 2506 children (56.4% of the eligible population). 
The proportion of children with an ASQ result 
below threshold at 24-26, 27-31, and 32-34 weeks’ 
gestation were 50.2% (44.5% to 55.8%), 40.7% 
(38.3% to 43.2%), and 36.2% (32.4% to 40.1%), 
respectively. Survival without severe or moderate 
neuromotor or sensory disabilities among live births 
increased between 1997 and 2011, from 45.5% 
(39.2% to 51.8%) to 62.3% (57.1% to 67.5%) at 25-
26 weeks’ gestation, but no change was observed at 
22-24 weeks’ gestation. At 32-34 weeks’ gestation, 
there was a non-statistically significant increase in 
survival without severe or moderate neuromotor or 
sensory disabilities (P=0.61), but the proportion of 
survivors with cerebral palsy declined (P=0.01).
CONCLUSIONS
In this large cohort of preterm infants, rates of survival 
and survival without severe or moderate neuromotor 
or sensory disabilities have increased during the past 
two decades, but these children remain at high risk of 
developmental delay.
Introduction
Survival of preterm babies has increased worldwide, 
with a concomitant decrease in severe neonatal 
morbidity.1-4 However, the risk of neurodevelopmental 
and behavioural disabilities remains high in 
children5-10 and in adults who were born preterm.11 12 
At extremely low gestations, ethical questions are 
crucial, and most recent national cohort studies have 
focused exclusively on extremely preterm birth.5 6 8 13-15 
Controversies over treatment decisions are described.16 
During the past two decades, countries with active 
perinatal care at extremely low gestation (eg, USA,15 
England,5 Sweden,6) have reported improvements in 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Survival of preterm neonates has increased worldwide, with a concomitant 
decrease in severe neonatal morbidities
Recent studies on neurodevelopmental outcomes of children born in the 2000s 
have focused on extremely preterm children, but outcomes of children born very 
and moderately preterm have rarely been reported
Identifying children at risk of later developmental delay who were born 
extremely, very, or moderately preterm is challenging
WhAT ThIS STudy AddS
In France from 1997 to 2011, severe neonatal morbidities in children born 
preterm decreased, accompanied by a statistically significant increase in survival 
without severe or moderate neuromotor or sensory disabilities at age 2 years
Despite improvements in neuromotor and sensory outcomes, a high number of 
children born before 34 weeks are at risk of developmental delay
Depending on gestational age, between half and one third of children 
born preterm will need formal developmental evaluation; using parental 
questionnaires as a first step approach to assess development may allow clinical 
resources to be focussed on those most likely to benefit
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outcomes for periviable infants (infants born at 22-
25 weeks’ gestation). Despite these improvements, 
survival without neurodevelopmental impairment at 
2-2.5 years was 20% in the USA for infants born at 22-
24 weeks’ gestation,15 and 34% and 42% in England5 
and Sweden,6 respectively, for infants born at 22-
26 weeks’ gestation. Results from countries without 
recommendations for active perinatal care at extremely 
low gestation have been less frequently reported.17 In 
absolute numbers, infants born very and moderately 
preterm represent a larger proportion of preterm births 
accounting for more children with motor, cognitive, or 
behavioural deficits and learning disabilities.18 19 These 
populations of very and moderately preterm neonates 
have been poorly investigated, but knowledge of 
specific developmental domains affected at preschool 
age could lead to targeted intervention and prevention 
of later disabilities, as timely intervention has a 
positive influence on cognitive outcome in infancy.20 
Updated information is therefore needed on outcomes 
for infants born at different gestational ages and in 
different settings to guide health policy, advise doctors 
in perinatal management, provide comprehensive 
information to facilitate parents’ involvement in shared 
decision making, and benchmark outcomes.21
Developmental delay rather than survival is now 
recognised as the main problem in children born 
preterm.5 6 10 15 Early identification of children at risk 
of later developmental difficulties may increase access 
to formal evaluation and subsequent intervention, 
potentially influencing the course of otherwise 
persistent difficulties.22 The Bayley Scales of Infant 
Development is usually the assessment of choice for 
neurodevelopmental evaluation between 18 and 30 
months.5 6 15 However, it is costly and time consuming, 
requires trained staff, and cannot be applied routinely 
to all children born preterm, particularly at more 
than 32 weeks’ gestation where numbers are much 
greater. Alternative tools that can effectively screen 
for developmental delay are therefore needed. 
Parental questionnaires are increasingly popular to 
assess development, as they are easy to administer 
and interpret, have a short completion time, and can 
decrease medical expenditure. In addition, they may be 
used in the community, have the capacity to facilitate 
parental involvement, and enable clinicians to focus 
on those children suspected of having developmental 
delay and hence needing further developmental 
assessment.23 24 The Ages and Stages Questionnaire 
(ASQ) is the most commonly used parent completed 
developmental screening test worldwide, and it is 
accepted by the American Academy of Paediatrics as 
a valid developmental screening tool25; it has been 
translated to, and validated in, French26 and there are 
arguments to support the cross cultural validity of the 
ASQ for other European countries.27 It could thus be 
useful for both large cohort studies and routine follow-
up as a first step approach to increase early detection 
of neurodevelopmental delay. However, its use in a 
national population of preterm children has never 
been evaluated.
The 2011 EPIPAGE-2 study is a national cohort study, 
designed to investigate outcomes and their changes 
over the past 15 years for children born from 22-34 
weeks’ gestation.28 In the original EPIPAGE cohort, data 
were collected on all very preterm births in nine French 
regions during 199729 and the surviving children 
were assessed at age 5 and 8 years.18 19 Substantial 
improvements in neonatal survival, accompanied by 
a large reduction in severe neonatal morbidity, have 
already been reported, although survival remained 
low before 25 weeks’ gestation compared with 
other countries.2 In the present study, we analysed 
neuromotor, sensory, and neurodevelopmental 
outcomes at 2 years corrected age, based on medical 
and parental evaluation of development using ASQ, 
for children born alive from 22-34 weeks’ gestation 
included in the EPIPAGE-2 cohort. We compared rates 
of survival, survival without neuromotor and sensory 
disabilities, and cerebral palsy in children born alive 
during 1997.
Methods
Study design and population
EPIPAGE-2 is a prospective national population based 
cohort scheduled to follow preterm children up to 
the age of 12 years. Infants born at 22-34 completed 
weeks’ gestation in all maternity units in 25 French 
regions (21 of the 22 metropolitan regions and all four 
overseas regions) were eligible for inclusion. The only 
region that did not participate accounted for 2% of 
births in France in 2011.28 Recruitment took place at 
birth and children were included in the study and data 
collected only after families had received information 
and agreed to participate in the study. Hence, for 
children whose parents declined participation, only 
status at birth, mortality, and limited perinatal data 
were available. The study began on 28 March 2011. 
Infants born at 22-26 weeks’ gestation were recruited 
during an eight month period, those born at 27-31 
weeks’ gestation during a six month period, and those 
born at 32-34 weeks’ gestation during a five week 
period.28 All survivors were enrolled for longitudinal 
follow-up and included in the study at 2 years corrected 
age if parents consented.
Data collection and evaluation methods
Data for children at 2 years corrected age were 
collected by using two standardised questionnaires: 
one completed by the referring doctor and the other by 
the parents.
Cerebral palsy and sensory deficits
We extracted data for cerebral palsy from the medical 
questionnaire, including information on major 
developmental steps (head control, sitting, standing, 
walking, and quality of gait), trunk and limb tone 
(low, normal, increased), and other abnormal 
neurological signs (see web appendix 1). Questions 
were pre-coded to minimise the risk of ambiguous 
answers. Questionnaires were similar in 1997 and 
2011 to facilitate comparisons. Cerebral palsy was 
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defined according to the diagnostic criteria of the 
Surveillance of Cerebral Palsy in Europe (SCPE) 
network,30 and motor ability was graded by using the 
five level Gross Motor Function Classification System 
(GMFCS).31 We also report the proportion of children 
with ambulatory cerebral palsy, defined as those with 
cerebral palsy who were walking at 2 years of age, with 
or without aids. Paediatricians in charge of routine 
follow-up performed the examinations. If a routine 
follow-up was unavailable, parents were asked to get 
their practitioner of choice to complete the medical 
questionnaire to ensure higher follow-up rates. Three 
of the authors (VP, FBL, and SM) separately reviewed 
ambiguous cases, with agreement on discrepancies 
reached in a consensus meeting. Data on vision 
and hearing were obtained from medical reports 
available during the medical examination. In cases 
of blindness, visual impairment was classified as 
severe (bilateral) or moderate (unilateral). Squinting 
or the need for glasses was also recorded. In cases of 
deafness, auditory impairment was classified as severe 
(bilateral) or moderate (unilateral). Severe neuromotor 
or sensory disabilities included any of GMFCS level 3-5 
cerebral palsy or severe visual or auditory impairment; 
moderate disability included GMFCS level 2 cerebral 
palsy with or without moderate visual or auditory 
impairment. Children without severe or moderate 
neuromotor or sensory disabilities were classified as 
having no or minor neuromotor or sensory disabilities.
Overall neurodevelopment
The child’s development was assessed with the second 
version of the 24 month Ages and Stages Questionnaire 
(ASQ) validated in France26 and completed by parents; 
data were analysed if completed between 22 and 26 
months corrected age in children without cerebral 
palsy, deafness, blindness, or severe congenital brain 
malformations. Each questionnaire includes 30 items 
covering five developmental domains: communication 
abilities, gross motor skills, fine motor skills, problem 
solving abilities, and personal-social skills. Items are 
scored on a three point scale depending on whether 
the child performs the task: yes (10 points), sometimes 
(5 points), or not yet (0 points). Responses are summed 
to give a score of 0 to 60 for each domain and an overall 
maximum ASQ score of 300 points. Analyses were 
based on domain specific scores, using established 
screening cut-off points: an ASQ score below threshold 
was defined as a score lower than 2 standard deviations 
from the mean on any of the five domains.24 We also 
report the number and nature of domains with scores 
below threshold.
Other major disabilities at 2 years corrected age
Major disabilities affecting respiratory or 
gastrointestinal systems were recorded. Respiratory 
disability was defined as the need for continuous 
respiratory support or oxygen and gastrointestinal 
disability as the need for parenteral nutrition or enteral 
feeding through a nasogastric tube or gastrostomy, or 
both.32
Comparison of 1997 and 2011 EPIPAGE cohorts
Children eligible for comparison were those born 
alive at 22-34 weeks’ gestation from the 1997 and 
2011 cohorts in the nine regions participating in both 
studies.29 Outcome measures at 2 years corrected 
age were rates of survival, survival without severe or 
moderate neuromotor or sensory disabilities among 
live births, and cerebral palsy among survivors.
Data management and statistics
Results among live births and at 2 years are presented by 
gestational age grouping (22-26, 27-31, combined 22-
31, and 32-34 weeks’ gestation for survival analyses; 
24-26, 27-31, combined 24-31, and 32-34 weeks’ 
gestation for disability analyses), and by week for 
those born at 22-26 weeks’ gestation. Firstly, summary 
data on maternal characteristics (maternal age, birth 
outside of France, and parents’ socioeconomic status), 
obstetric (multiple pregnancy, antenatal steroids, and 
caesarean section), and neonatal factors (sex, small for 
gestational age, inborn status, surfactant, postnatal 
steroids, severe neonatal morbidities, and breast milk 
at discharge) are presented for children whose parents 
gave consent at birth and for survivors included in the 
study at 2 years corrected age; data were compared 
with those who did not participate in the initial study 
or were lost to follow-up. Socioeconomic status was 
defined as the highest occupational status of the 
mother and father, or mother only if a single parent, 
small for gestational age as birth weight <10th centile 
for gestational age and sex based on French “EPOPé” 
intrauterine growth curves,33 and severe neonatal 
morbidities as severe bronchopulmonary dysplasia, 
necrotising enterocolitis (Bell stages 2-3), severe 
retinopathy of prematurity stage >3, or any of the 
following severe cerebral abnormalities on cranial 
ultrasonography: intraventricular haemorrhage grade 
III or IV or cystic periventricular leukomalacia.2 
Secondly, for children examined at 2 years corrected 
age, percentages of cerebral palsy, visual and hearing 
impairments, and ASQ below threshold are presented. 
Thirdly, among live births, rates of total survival are 
reported for all cases, and survival without severe 
or moderate neuromotor and sensory disabilities 
for all cases after multiple imputation to account for 
selective dropouts and missing information at 2 years 
corrected age; among survivors, rates are reported 
for both complete cases and all cases after multiple 
imputation. Multiple imputation was performed as 
a sensitivity analysis. Missing data were imputed by 
chained equations using the SAS “MI” procedure.34 
Imputation model variables included both those 
potentially predicting non-response and/or outcomes 
(gestational age, maternal age and country of birth, 
parity, parental socioeconomic status, antenatal 
steroids, caesarean section, multiple pregnancy, sex, 
small for gestational age, severe congenital brain 
malformation, inborn status, surfactant, postnatal 
steroids, severe neonatal morbidities, use of breast 
milk at discharge), and outcomes (cerebral palsy, 
neuromotor or sensory disabilities, and ASQ). For 
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ASQ, missing domains (defined as binary variables 
(yes/no) for a score below threshold in each of the 
five domains) were separately imputed to account 
for partially completed questionnaires. Overall ASQ 
score was then estimated using the domain specific 
imputed datasets for infants without cerebral palsy, 
deafness, blindness, or severe congenital anomalies. 
Socioeconomic data were imputed using multinomial 
models. Other variables with missing data, all binary, 
were imputed using logistic regression. We generated 
50 independent imputed datasets with 30 iterations 
each. Estimates were pooled according to Rubin’s 
rule.35 Further details are available in web appendix 2. 
Fourthly, to document trends over time, we compared 
1997 and 2011 rates of survival, survival without 
severe or moderate neuromotor or sensory disabilities 
among live births, and cerebral palsy among survivors 
and calculated the difference between 1997 and 
2011 adjusted for baseline factors that may influence 
outcomes (gestational age, small for gestational age, 
sex, and multiple pregnancy status). Risk differences 
were estimated using a binomial model with identity 
link. Cohort data were obtained from the entire year in 
1997 and from 28 March 2011 to 31 December 2011. 
Analyses for 1997 were run for the entire year and then 
separately for April to December. Results did not differ, 
and thus 1997 data are presented for the whole year. 
To better understand the link between the evolution 
of outcomes and variations in practice, we compared 
the maternal characteristics and obstetric and 
neonatal factors of the 1997 and 2011 populations. 
Finally, factors associated with cerebral palsy or an 
ASQ score below threshold were studied for complete 
cases by using multiple logistic regression models. 
Variables entered into the models were gestational 
age, sex, single or multiple pregnancy status, small for 
gestational age, and parental socioeconomic status.
Percentages are given with their exact 95% binomial 
confidence intervals, and medians with interquartile 
ranges. For analyses performed on the overall cohort, 
we used weighted percentages and gestational age 
adjustments in the multivariable analyses to account 
for differences in sampling times between gestational 
age groups. We compared groups of infants using the 
χ2 test. All tests were two sided; P<0.05 was considered 
statistically significant. Statistical analyses were 
performed using SAS v9.4 software.
Patient involvement
Patients were not involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for design of the study. 
Parents showed overwhelming support for the 
study through high follow-up rates and by providing 
testimonials (displayed on the EPIPAGE-2 website at 
http://epipage2.inserm.fr/index.php/fr/cote-parents/
temoignages). EPIPAGE-2 maintains contact with 
parents in the cohort through letters, newsletters, and 
its website. National parents’ associations assisted 
with the dissemination of the results.
Results
EPIPAGE-2: neurodevelopmental outcomes and 
overall survival at 2 years corrected age
Population
Parental consent was obtained for inclusion of 5170 
of 5567 liveborn babies between 22 and 34 weeks’ 
gestation in the EPIPAGE-2 study. All survivors (n=4467) 
were enrolled for longitudinal follow-up; 24 died post-
discharge and the parents of 244 declined further 
participation. Thus, 4199 children were included in the 
follow-up study. Among these 4199 children, medical 
questionnaires were available for 3600 (81.0% of all 
children) and parental questionnaires for 3689 (83.0% 
of all children) (fig 1). Overall, 148 neonates were born 
alive at 22-23 weeks’ gestation and all but one died in 
the neonatal period. This survivor was born at 23 weeks’ 
gestation and six days and was therefore included with 
those born at 24 weeks’ gestation.
Web appendix 3 shows the comparisons between 
children with and without parental consent at 
birth for participation, as well as children with 
and without cerebral palsy or ASQ data available. 
Parental questionnaire at 2 years
corrected age (n=3689; 83.0%)
ASQ completed between 22 and 26 months'
corrected age (n=2637; 59.4%)
Medical questionnaire at 2 years
corrected age (n=3600; 81.0%)
Liveborn infants at 22-34 completed weeks' gestation (n=5567)
Liveborn infants at 22-34 completed weeks' gestation with parental consent (n=5170)
Discharged home alive and eligible for follow-up* (n=4467)
Survivors at 2 years eligible for follow-up (n=4443)
Parents refused participation (n=397)
Excluded (n=703):
  Died in delivery room (n=290)
  Died in neonatal intensive care unit (n=413)
Died between discharge and 2 years (n=24)
Survivors at 2 years included in follow-up† (n=4199)
Follow-up refused by parents (n=244)
Excluded (n=1052):
  ASQ not completed (n=279)
  ASQ completed outside the expected
    age (n=773)
Cerebral palsy data available (n=3599; 81.0%)
Hearing data available (n=3517; 79.2%)
Vision data available (n=3400; 76.5%)
ASQ data used in analysis (n=2506; 56.4%)
Cerebral palsy, deafness, blindness,
or severe congenital brain
malformations (n=131)
Fig 1 | Flowchart of study population: EPIPAGE-2 cohort at 2 years corrected age. 
ASQ=Ages and Stages Questionnaire. Percentages in parentheses are number of 
events/number of survivors at 2 years eligible for the study (n=4443). *No survivors at 
22 weeks and only one survivor at 23 weeks and six days. †Of the 4199 survivors at 2 
years included in follow-up, 2545 had data available for both cerebral palsy and ASQ 
between 22 and 26 months corrected age, cerebral palsy data only were available for 
1054, ASQ data only for 92, and no data were available for 508 children
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Neonates whose parents refused participation were 
born more frequently at 32-34 weeks’ gestation and 
to mothers of lower socioeconomic status. Compared 
with responders, children with unavailable cerebral 
palsy or ASQ data were more frequently born at 32-
34 weeks’ gestation, after a singleton pregnancy, to 
younger mothers, mothers born outside France, or to 
mothers of a lower socioeconomic status, and were less 
frequently fed breast milk at discharge; however, the 
main neonatal outcomes did not differ between groups. 
Web appendix 4 shows the characteristics of children 
with data about cerebral palsy status according to 
gestational age group.
Cerebral palsy and sensory outcomes
Medical examinations were performed at a median of 
24.2 months corrected age (interquartile range 23.1-
25.7) and by a paediatrician in 88.0%, 80.2%, and 
59.8% of children born at 24-26, 27-31, and 32-34 
weeks’ gestation, respectively. Information on cerebral 
palsy was available from 3599/3600 questionnaires 
(2714 and 885 for children born at 24-31 and 32-
34 weeks’ gestation, respectively). Cerebral palsy 
was diagnosed in 137 children: bilateral spastic 
cerebral palsy in 120 (weighted %, 82.3%), unilateral 
spastic cerebral palsy in 15 (weighted %, 16.5%), 
and dyskinetic or unclassifiable cerebral palsy in 
2 (weighted %, 1.2%). The overall rate of cerebral 
palsy was 4.6% at 24-31 weeks’ gestation, decreasing 
from 6.9% to 4.3% between 24-26 and 27-31 weeks’ 
gestation. At 32-34 weeks’ gestation, the cerebral palsy 
rate was 1.0% (table 1). Among those with cerebral 
palsy, 15/31 (48.4%), 51/97 (52.6%), and 7/9 
(77.8%) at 24-26, 27-31, and 32-34 weeks’ gestation, 
respectively, were ambulatory forms of cerebral palsy. 
Severe auditory or visual impairment was reported in 
fewer than 1% of children included in the cohort. The 
proportion of children wearing glasses decreased with 
increasing gestational age.
Neurodevelopmental outcome
Parental questionnaires were collected at a median 
of 24.3 months corrected age (interquartile range 
23.5-26.3). Among the 3689 parental questionnaires 
available, ASQ analysis was possible for 2637 children 
(59.4% of all children). In total, 131 questionnaires 
were excluded because of cerebral palsy, deafness 
or blindness (n=121), or severe congenital brain 
malformations (n=10), leaving 2506 questionnaires in 
the complete case analysis (1884 and 622 for children 
born at 24-31 and 32-34 weeks’ gestation, respectively). 
Median ASQ scores increased from 223 at 24-26 weeks’ 
gestation to 235 at 32-34 weeks’ gestation (table 1). 
An ASQ score below threshold was observed in 50.2%, 
40.7%, and 36.2% of children born at 24-26, 27-31, 
and 32-34 weeks’ gestation, respectively; 7.7%, 3.8%, 
and 1.8% of these respective groups had a score below 
threshold in 4-5 ASQ domains. Web appendix 8 shows 
the median total scores by number of domains below 
threshold. The domains most frequently scoring below 
threshold were communication and personal-social 
in all gestational age groups. Proportions of children 
scoring below the threshold in either of these domains 
decreased with increasing gestational age but were 
still 17.8% and 13.3%, respectively, at 32-34 weeks’ 
gestation. Although children with cerebral palsy were 
excluded, 16.6% of children born at 24-26 weeks’ 
gestation scored below the threshold in the gross 
motor domain compared with 5.1% at 32-34 weeks’ 
gestation.
Other major disabilities
Nine children out of 2667 with available data born 
at 24 to 31 weeks’ gestation (0.3%, 95% confidence 
interval 0.1% to 0.6%) still needed oxygen at 2 years 
corrected age, 28 of 2660 (1.0%, 0.6% to 1.4%) 
received enteral nutrition by tube or gastrostomy, 
and 3 out of 2652 (0.1%, 0.0% to 0.3%) received 
parenteral nutrition. The proportion of children fed by 
tube or gastrostomy was 2.7% (1.4% to 4.7%) at 24-26 
weeks’ gestation (12/447) and 0.7% (0.4 to 1.2) at 27-
31 weeks’ gestation (16/2218). Overall, 11 children 
out of 2470 with data available for all variables (0.4%, 
0.2% to 0.7%) had respiratory or gastrointestinal 
disabilities associated with cerebral palsy and/or 
deafness or blindness. Fewer than 0.5% of children 
born at 32-34 weeks’ gestation (4/885) had respiratory 
or gastrointestinal disabilities.
Overall survival at 2 years corrected age and dropout 
analyses
Among live births, survival at 2 years corrected age 
increased with increasing gestational age and, after 
multiple imputation, survival without severe or 
moderate neuromotor and sensory disabilities was 
48.5%, 90.0%, and 97.5% at 22-26, 27-31, and 32-
34 weeks’ gestation, respectively (table 2). Among 
survivors at 2 years corrected age, rates of cerebral 
palsy were only slightly modified after multiple 
imputation, but rates of ASQ scores below threshold 
increased in all gestational age groups after multiple 
imputation. Web appendix 5 presents the outcomes for 
children born at 24-26 weeks’ gestation by gestational 
week.
Comparison of the 1997 and 2011 EPIPAGE cohorts 
(nine regions)
Neonates born alive at 22-34 weeks’ gestation in the 
nine regions participating in both EPIPAGE studies 
totalled 3334 in 1997 and 2418 in 2011; 2262 (1997) 
and 1696 (2011) were alive at 2 years corrected 
age with outcome data available (table 3). Follow-
up rates at 2 years were 79.0% in 1997 and 82.2% 
in 2011. No infant born at 22-23 weeks’ gestation 
survived in these nine regions in either period. After 
adjustment for baseline characteristics, for children 
born at 22-31 weeks’ gestation, survival increased by 
6.0% (95% confidence interval, 3.5% to 8.5%), and 
survival without neuromotor or sensory impairment 
by 7.2% (4.7% to 9.8%); in children born at 24-31 
weeks’ gestation, cerebral palsy decreased by 3.3% 
(1.6% to 5.0%). Changes between the two periods for 
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Table 1 | Cerebral palsy, sensory disabilities, and results for Ages and Stages Questionnaire (ASQ) at 2 years corrected age by gestational age groups. 
Complete case analysis
Variables
24-31 weeks* 24-26 weeks* 27-31 weeks 32-34 weeks P value†
No of 
events/ 
No in group % (95% CI)
No of 
events/ 
No in group % (95% CI)
No of 
events/ 
No in group % (95% CI)
No of 
events/ 
No in group % (95% CI)
Cerebral palsy 128/2714 4.6 (3.9 to 5.5) 31/450 6.9 (4.7 to 9.6) 97/2264 4.3 (3.5 to 5.2) 9/885 1.0 (0.5 to 1.9) <0.001
GMFCS level:
 5 8/2714 0.3 (0.1 to 0.6) 3/450 0.7 (0.1 to 1.9) 5/2264 0.2 (0.1 to 0.5) 0/885 0.0 (NA)
 3 or 4 24/2714 0.9 (0.6 to 1.3) 5/450 1.1 (0.4 to 2.6) 19/2264 0.8 (0.5 to 1.3) 0/885 0.0 (NA)
 2 39/2714 1.4 (1.0 to 1.9) 12/450 2.7 (1.4 to 4.6) 27/2264 1.2 (0.8 to 1.7) 3/885 0.3 (0.1 to 1.0)
 1 57/2714 2.1 (1.6 to 2.7) 11/450 2.4 (1.2 to 4.3) 46/2264 2.0 (1.5 to 2.7) 6/885 0.7 (0.2 to 1.5)
Hearing
Deafness: 19/2651 0.7 (0.4 to 1.1) 6/442 1.4 (0.5 to 2.9) 13/2209 0.6 (0.3 to 1.0) 4/866 0.5 (0.1 to 1.2) 0.28
 Bilateral 13/2651 0.5 (0.2 to 0.8) 6/442 1.4 (0.5 to 2.9) 7/2209 0.3 (0.1 to 0.7) 4/866 0.5 (0.1 to 1.2)
 Unilateral 6/2651 0.2 (0.1 to 0.5) 0/442 0.0 (NA) 6/2209 0.3 (0.1 to 0.6) 0/866 0.0 (NA)
Vision
Blindness: 10/2553 0.4 (0.2 to 0.7) 3/421 0.7 (0.1 to 2.1) 7/2132 0.3 (0.1 to 0.7) 2/847 0.2 (0.0 to 0.9) 0.51
 Bilateral 5/2553 0.2 (0.1 to 0.4) 2/421 0.5 (0.1 to 1.7) 3/2132 0.1 (0.0 to 0.4) 1/847 0.1 (0.0 to 0.7)
 Unilateral 5/2553 0.2 (0.1 to 0.5) 1/421 0.2 (0.0 to 1.3) 4/2132 0.2 (0.1 to 0.5) 1/847 0.1 (0.0 to 0.7)
Squinting‡ 152/2533 5.9 (5.1 to 6.9) 30/416 7.2 (4.9 to 10.1) 122/2117 5.8 (4.8 to 6.8) 30/840 3.6 (2.4 to 5.1) 0.003
Wearing glasses‡ 180/2527 7.0 (6.1 to 8.1) 38/418 9.1 (6.5 to 12.3) 142/2109 6.7 (5.7 to 7.9) 35/842 4.2 (2.9 to 5.7) <0.001
Neuromotor or  
sensory  
disabilities§:
 Severe 45/2524 1.7 (1.3 to 2.3) 12/420 2.9 (1.5 to 4.9) 33/2104 1.6 (1.1 to 2.2) 5/834 0.6 (0.2 to 1.4) <0.001
 Moderate 48/2524 1.8 (1.4 to 2.5) 13/420 3.1 (1.7 to 5.2) 35/2104 1.7 (1.2 to 2.3) 3/834 0.4 (0.1 to 1.0)
  None or minor 
 disabilities
2431/2524 96.4 (95.6 to 97.1) 395/420 94.0 (91.3 to 96.1) 2036/2104 96.8 (95.9 to 97.5) 826/834 99.0 (98.1 to 99.6)
ASQ¶:
  Median  
(interquartile  
range) total  
ASQ score
1884 229 (199-255) 313 223 (185-250) 1571 230 (200-255) 622 235 (205-260) <0.001
  ASQ score  
below thresh-
old**
797/1884 42.0 (39.7 to 44.2) 157/313 50.2 (44.5 to 55.8) 640/1571 40.7 (38.3 to 43.2) 225/622 36.2 (32.4 to 40.1) <0.001
No of domains  
below threshold:
 0 1087/1884 58.0 (55.8 to 60.3) 156/313 49.8 (44.2 to 55.5) 931/1571 59.3 (56.8 to 61.7) 397/622 63.8 (59.9 to 67.6) <0.001
 1 441/1884 23.4 (21.5 to 25.4) 76/313 24.3 (19.6 to 29.4) 365/1571 23.2 (21.2 to 25.4) 139/622 22.3 (19.1 to 25.8)
 2 171/1884 8.9 (7.7 to 10.3) 38/313 12.1 (8.7 to 16.3) 133/1571 8.5 (7.1 to 10.0) 51/622 8.2 (6.2 to 10.6)
 3 101/1884 5.3 (4.4 to 6.4) 19/313 6.1 (3.7 to 9.3) 82/1571 5.2 (4.2 to 6.4) 24/622 3.9 (2.5 to 5.7)
 4 or 5 84/1884 4.3 (3.4 to 5.3) 24/313 7.7 (5.0 to 11.2) 60/1571 3.8 (2.9 to 4.9) 11/622 1.8 (0.9 to 3.1)
By domain:
 Communication 484/1884 25.3 (23.4 to 27.4) 106/313 33.9 (28.6 to 39.4) 378/1571 24.1 (22.0 to 26.3) 111/622 17.8 (14.9 to 21.1) <0.001
 Gross motor 204/1884 10.6 (9.2 to 12.0) 52/313 16.6 (12.7 to 21.2) 152/1571 9.7 (8.3 to 11.2) 32/622 5.1 (3.5 to 7.2) <0.001
 Fine motor 211/1884 11.2 (9.8 to 12.7) 38/313 12.1 (8.7 to 16.3) 173/1571 11.0 (9.5 to 12.7) 65/622 10.5 (8.2 to 13.1) 0.75
 Problem solving 217/1884 11.5 (10.1 to 13.0) 40/313 12.8 (9.3 to 17.0) 177/1571 11.3 (9.7 to 12.9) 68/622 10.9 (8.6 to 13.7) 0.69
 Personal-social 334/1884 17.4 (15.7 to 19.2) 78/313 24.9 (20.2 to 30.1) 256/1571 16.3 (14.5 to 18.2) 83/622 13.3 (10.8 to 16.3) <0.001
GMFCS=Gross Motor Function Classification System; NA=not applicable.
Denominators vary according to number of missing data for each variable. Percentages are weighted to account for differences in sampling process between gestational age groups. Data are 
presented by gestational age grouping: 24-26 and 27-31 (both italicised), combined 24-31, and 32-34 weeks’ gestation.
*Including one survivor born at 23 weeks and six days. Percentages are weighted to account for differences in sampling process between gestational age groups. 
†Comparison between gestational age groups 24-26 weeks, 27-31 weeks, and 32-34 weeks.
‡For children without blindness.
§Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level-2 and/
or unilateral deafness and/or unilateral blindness. Seven infants had associated severe or moderate cerebral palsy and sensory disabilities.
¶Infants with cerebral palsy, deafness, blindness, or severe congenital anomalies were excluded (n=131).
**For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 200924) was reported. If a score was below threshold in at least 
one domain, the global ASQ was considered below threshold.
Overall, the rate of survivors with no or minor neuromotor or sensory disabilities increased from 94.0% at 24-26 weeks’ gestation to 96.8% at 27-31 weeks’ gestation and 99.0% at 32-34 
weeks’ gestation.
both survival, survival without neuromotor or sensory 
disabilities, and rates of cerebral palsy in survivors 
were not statistically significant for children born at 24 
weeks’ gestation, but noticeable improvements were 
seen at 25-26 weeks and, to a lesser extent, at 27-31 
weeks. Web appendix 6 presents the data for survival 
and survival without neuromotor or sensory disabilities 
by gestational weeks. At 32-34 weeks’ gestation, the 
rate of cerebral palsy declined by 3.3% (0.7% to 5.9%), 
but survival and survival without severe neuromotor or 
sensory impairment were similar.
Table 4 shows the changes between 1997 and 2011 
in maternal characteristics and obstetric and neonatal 
factors. In 2011, mothers were older and parents were 
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Table 2 | Survival, rates of cerebral palsy, and Ages and Stages Questionnaire (ASQ) scores below threshold at 2 years corrected age among complete 
cases and after multiple imputation by gestational age groups
Variables Data analysis
% (95% CI)
22-31 weeks 22-26 weeks 27-31 weeks 32-34 weeks
Live births
Survival at 2 years corrected age* Complete cases 84.3 (83.2 to 85.4) 51.7 (48.6 to 54.7) 93.1 (92.1 to 94.0) 98.6 (97.8 to 99.2)
Survival without neuromotor or sensory  
disabilities at 2 years corrected age†
Multiple imputation 81.2 (79.9 to 82.4) 48.5 (45.4 to 51.6) 90.0 (88.8 to 91.1) 97.5 (96.4 to 98.5)
Survivors at 2 years corrected age‡
Cerebral palsy Complete cases 4.6 (3.9 to 5.5) 6.9 (4.7 to 9.6) 4.3 (3.5 to 5.2) 1.0 (0.5 to 1.9)
Multiple imputation 4.8 (4.0 to 5.6) 7.2 (4.9 to 9.6) 4.4 (3.6 to 5.3) 1.1 (0.4 to 1.7)
ASQ score below threshold§ Complete cases 42.0 (39.7 to 44.2) 50.2 (44.5 to 55.8) 40.7 (38.3 to 43.2) 36.2 (32.4 to 40.1)
Multiple imputation 47.8 (45.5 to 50.2) 55.8 (50.8 to 60.9) 46.7 (44.2 to 49.2) 42.7 (38.7 to 46.7)
Total percentages are weighted to account for differences in sampling process between gestational age groups. Data are presented by gestational age grouping: 22-26 and 27-31 (both 
italicised), combined 24-31, and 32-34 weeks’ gestation.
*No missing data for survival at 2 years.
†Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral blindness; moderate=cerebral palsy GMFCS level 2 and/
or unilateral deafness and/or unilateral blindness. Seven infants had associated severe or moderate cerebral palsy and sensory disabilities. For some surviving children who were lost to follow-up, 
the disability status was unknown, and consequently only multiple imputation analysis was possible.
‡All but one neonate born at 22-23 weeks died.
§For each domain, a score lower than 2 standard deviations from the mean, using established screening cut-off points (Squire 200924) was reported. If a score was below threshold in at least one 
domain, the global ASQ was considered below threshold. Infants with cerebral palsy, deafness, blindness, or severe congenital anomalies were excluded (n=131).
of higher socioeconomic status, but fewer mothers were 
born in France. The proportions of children receiving 
antenatal steroids and surfactant increased while the 
proportion of children receiving postnatal steroids 
decreased. In addition, a lower proportion of children had 
severe neonatal morbidities in all gestational age groups.
Factors associated with cerebral palsy and ASQ 
scores below threshold in the EPIPAGE-2 cohort
We examined factors associated with cerebral palsy 
and ASQ scores below threshold in children born 
at 24-31 weeks’ gestation (see web appendix  7). 
Gestational age and small for gestational age were 
important predictors of cerebral palsy; extremely low 
gestational age, male sex, small for gestational age, 
and low parental socioeconomic status increased the 
risk of an ASQ score below threshold. For those born 
at 32-34 weeks’ gestation, cases of cerebral palsy were 
insufficient to study factors associated with cerebral 
palsy; only small for gestational age and low parental 
socioeconomic status were associated with ASQ scores 
below threshold (data not shown).
Table 3 | Outcomes for children included in the nine regions participating in EPIPAGE (1997) and EPIPAGE-2 (2011) studies by weeks’ gestational  
age (GA)
Outcomes
1997 2011 (EPIPAGE-1 regions)
% difference 2011 v 
1997* (95% CI) P value
% adjusted  
difference 2011 v  
1997*,† (95% CI) P value
No of events/ 
No in group % (95% CI)
No of events/ 
No in group % (95% CI)
Live births
Survival at 2 years corrected age (weeks’ GA)‡:
 22-31 1690/2123 79.4 (77.5 to 81.2) 1520/1861 84.1 (82.4 to 85.8) 4.8 (2.6 to 6.9) <0.001 6.0 (3.5 to 8.5) <0.001
  22-23 0/46 0.0 (NA) 0/76 0.0 (NA) 0.0 - 0.0 -
  24 13/42 32.7 (18.5 to 49.7) 28/96 29.2 (20.3 to 39.3) −3.5 (−19.2 to 12.1) 0.66 −0.6 (−17.0 to 15.8) 0.94
  25-26 147/277 53.2 (46.8 to 59.5) 231/347 66.6 (61.3 to 71.5) 13.4 (6.2 to 20.6) <0.001 12.1 (4.9 to 19.2) 0.001
  27-31 1530/1758 86.8 (85.0 to 88.4) 1261/1342 94.0 (92.6 to 95.2) 7.2 (5.4 to 9.0) <0.001 7.0 (5.3 to 8.8) <0.001
 32-34 1175/1211 97.2 (95.6 to 98.3) 544/557 97.7 (96.0 to 98.8) 0.5 (−0.2 to 1.2) 0.17 0.0 (−0.9 to 0.8) 0.73
Survival without neuromotor or sensory disabilities at 2 years corrected age (weeks’ GA)§:
 22-31 74.5 (72.5 to 76.5) 80.5 (78.7 to 82.3) 6.1 (3.7 to 8.5) <0.001 7.2 (4.7 to 9.8) <0.001
  22-23 0.0 (NA) 0.0 (NA) 0.0 - 0.0 -
  24 29.0 (12.3 to 45.7) 25.8 (16.9 to 34.6) −3.2 (−20.3 to 13.8) 0.71 −1.9 (−18.9 to 15.2) 0.83
  25-26 45.5 (39.2 to 51.8) 62.3 (57.1 to 67.5) 16.8 (3.8 to 9.4) <0.001 17.6 (10.2 to 24.9) <0.001
  27-31 82.1 (80.2 to 84.1) 90.3 (88.7 to 92.0) 8.2 (6.0 to 10.4) <0.001 6.4 (1.1 to 4.4) <0.001
 32-34 95.7 (94.1 to 97.4) 96.8 (95.2 to 98.4) 1.1 (−0.3 to 2.2) 0.095 0.4 (−1.2 to 2.1) 0.61
Survivors at 2 years corrected age‡
Cerebral palsy (weeks’ GA):
 24-31 129/1415 9.0 (7.5 to 10.6) 71/1280 5.4 (4.2 to 6.8) −3.6 (−5.3 to −1.8) <0.001 −3.3 (−5.0 to −1.6) <0.001
  24 1/11 7.1 (0.1 to 38.8) 4/26 15.4 (4.4 to 34.9) 8.2 (−11.1 to 27.6) 0.40 11.4 (−22.0 to 44.7) 0.50
  25-26 23/133 17.8 (11.4 to 25.9) 15/191 7.9 (4.5 to 12.6) −9.9 (−16.9 to −2.9) 0.005 −8.6 (−16.5 to −0.6) 0.035
  27-31 105/1271 8.0 (6.6 to 9.7) 52/1063 4.9 (3.7 to 6.4) −3.2 (−4.9 to −1.4) <0.001 −2.7 (−4.5 to −0.9) 0.003
 32-34 30/847 2.8 (1.5 to 4.7) 1/416 0.2 (0.0 to 1.3) −2.6 (−3.2 to −1.9) <0.001 −3.3 (−5.9 to −0.7) 0.014
Percentages are weighted to account for differences in sampling process between gestational age groups.
* Risk differences were estimated with a binomial model with identity link.
† Adjusted for gestational age, sex, small for gestational age, and multiple pregnancy.
‡ Complete cases analysis. No survivors at 22-23 weeks in the nine regions participating in both EPIPAGE studies.
§ Results based on data using multiple imputation. Severe or moderate neuromotor or sensory disability: severe=cerebral palsy GMFCS levels 3-5 and/or bilateral deafness and/or bilateral 
blindness; moderate=cerebral palsy GMFCS level-2 and/or unilateral deafness and/or unilateral blindness. 
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discussion
In this French population based cohort of neonates 
born at 22-34 weeks’ gestation in 2011, rates of 
survival without severe or moderate neuromotor 
and sensory disabilities at 2 years corrected age 
of 48.5%, 90.0%, and 97.5% were observed for 
children born at 22-26, 27-31, and 32-34 weeks’ 
gestation, respectively. Only one child born at 22-
Table 4 | Comparison of maternal characteristics and obstetric and neonatal factors between 1997 and 2011 for live 
births included in the nine regions participating in both EPIPAGE studies by weeks’ gestational age (GA). Complete 
cases analysis. Data are number of events/number in group and percentage unless stated otherwise
Variables 1997 2011 (EPIPAGE-1 regions) P value*
Maternal characteristics
Maternal age (years):
 <25 770/3300 22.3 456/2416 16.3 <0.001
 25-34 2015/3300 61.8 1446/2416 61.0
 ≥35 515/3300 15.9 514/2416 22.7
Birth outside of France 477/2978 17.6 655/2344 25.4 <0.001
Parents’ socioeconomic status†:
 Professional/Intermediate 1113/3065 38.3 968/2269 44.8 <0.001
 Others 1746/3065 54.9 1222/2269 51.8
 Unknown occupation 206/3065 6.8 79/2269 3.4
Obstetric factors
Multiple pregnancy 1048/3334 31.5 815/2418 35.7 0.020
Antenatal steroids (weeks’ GA):
 22-31 1478/2054 73.2 1464/1833 80.9 <0.001
  22-23 9/44 24.1 6/72 8.3 0.024
  24 15/40 38.0 54/95 56.8 0.056
  25-26 166/269 63.7 276/342 80.7 <0.001
  27-31 1288/1701 76.9 1128/1324 85.2 <0.001
 32-34 836/1179 69.0 431/543 79.4 <0.001
Caesarean section (weeks’ GA):
 22-31 1127/2100 52.8 1043/1846 58.5 <0.001
  22-23 1/46 1.8 2/73 2.7 0.71
  24 1/41 2.0 12/92 13.0 0.027
  25-26 72/275 25.9 138/342 40.4 <0.001
  27-31 1053/1738 59.7 891/1339 66.5 <0.001
 32-34 714/1207 53.1 278/555 50.1 0.30
Neonatal factors
Male 1789/3328 54.0 1303/2418 53.9 0.96
Small for gestational age‡ 1243/3328 36.7 799/2416 33.3 0.061
Surfactant (weeks’ GA)§:
 22-31 992/1967 49.7 1116/1694 63.9 <0.001
  22-23 5/6 83.3 3/4 75.0 0.75
  24 23/27 82.9 52/53 98.1 0.013
  25-26 181/233 78.2 319/324 98.5 <0.001
  27-31 783/1701 45.1 742/1313 56.5 <0.001
 32-34 168/1170 8.5 64/536 11.9 0.037
Postnatal steroids (weeks’ GA)§:
 22-31 459/1965 23.6 151/1656 8.2 <0.001
  22-23 1/6 16.7 0/4 0.0
  24 13/27 48.6 15/51 29.4 0.11
  25-26 126/232 55.0 77/319 24.1 <0.001
  27-31 319/1700 18.9 59/1282 4.6 <0.001
 32-34 26/1169 1.2 1/531 0.2 0.025
Severe neonatal morbidities (weeks’ 
GA)§¶:
 22-31 693/1906 36.1 303/1602 17.5 <0.001
  22-23 6/6 100.0 0/2 0.0
  24 26/27 97.1 28/47 59.6 <0.001
  25-26 173/229 74.4 119/293 40.6 <0.001
  27-31 488/1644 29.4 156/1260 12.4 <0.001
 32-34 83/1123 5.6 8/515 1.6 <0.001
Denominators vary according to number of missing data for each variable. Percentages are weighted to account for differences in sampling process 
between gestational age groups.
*Comparison between 1997 and 2011. 
†Defined as highest occupational status of mother and father, or mother only if living alone. 
‡Small for gestational age was defined as birth weight less than the 10th centile for gestational age and sex based on French intrauterine “EPOPé” 
growth curves (Ego et al 201633). 
§Related to infants admitted to neonatal intensive care units. 
¶Severe neonatal morbidity was defined as severe bronchopulmonary dysplasia or necrotising enterocolitis stage 2-3 or severe retinopathy of 
prematurity stage >3 or any of the following severe cerebral abnormalities on cranial ultrasonography: intraventricular haemorrhage grade III or IV or 
cystic periventricular leukomalacia (Ancel et al 20152).
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23 weeks’ gestation survived. After adjustment for 
changes in the baseline characteristics of infants over 
time, rates of survival and survival without severe 
or moderate neuromotor and sensory disabilities at 
2 years corrected age increased between 1997 and 
2011 for children born at 22-31 weeks’ gestation 
but no change was found for children born at 24 
weeks’ gestation or earlier. Rates of cerebral palsy 
decreased by 3.3% between the two epochs, which 
was statistically significant, at both 24-31 and 
32-34 weeks’ gestation. After excluding children 
with cerebral palsy, blindness, deafness, or severe 
congenital brain malformations, 50.2%, 40.7%, 
and 36.2% of children born at 24-26, 27-31, and 
32-34 weeks’ gestation, respectively, had Ages and 
Stages Questionnaire (ASQ) scores below threshold 
and were considered at risk of developmental delay. 
Communication and personal-social domains were 
the domains most frequently scoring below threshold.
Strengths and limitations of this study
The strengths of the EPIPAGE-2 study include the 
population based cohort design, at a national level, 
with prospective enrolment of a large number of 
infants born not only extremely preterm but also 
very and moderately preterm, whose outcome has 
been infrequently reported. We used standardised 
definitions of outcomes following international 
recommendations,21 thus allowing comparison with 
other international cohorts. In addition, we obtained 
face to face assessments to diagnose cerebral palsy 
and we explored the full range of development with 
the ASQ to better understand profiles of development 
by gestational age group.
The main limitation of the study was the number of 
children lost to follow-up, although the follow-up rate 
was high in terms of the size of the cohort. Results from 
other studies36 suggest an excess of poorly performing 
children among those not evaluated because the 
parents of children from more disadvantaged families 
are more often non-responders. We also found a social 
bias in participation, with more families of a low 
socioeconomic status initially refusing participation 
or not responding at two years. We used multiple 
imputation to account for missing data. This did 
not modify the rate of cerebral palsy but showed a 
consistent increase across gestational age groups in 
the proportion of children with ASQ scores below 
threshold, similar to the impact of socioeconomic 
status on development seen in other studies.5 In 
addition, because of the number of doctors involved 
in the study, their ability to diagnose cerebral palsy 
might have varied. However, this was a pragmatic 
choice that means our results also reflect how cerebral 
palsy is diagnosed in routine practice. Milder forms of 
cerebral palsy may have been missed but most of the 
doctors were paediatricians involved in the routine 
follow-up of children born preterm, and a standardised 
questionnaire was used to minimise ambiguous 
answers. Finally, the lack of cognitive evaluation by 
trained psychologists may limit comparisons with 
other cohorts. We used the ASQ, a parent based 
developmental questionnaire, reported as useful to 
identify children at risk of having a developmental 
quotient less than 85,37 with a sensitivity of 87% and a 
specificity of 77%.24 However, the correlation between 
the ASQ score and a standardised, professionally 
administered developmental test score is higher in 
preterm children than term born children,38 increases 
with increasing age at assessment,38 and two years 
seems a reliable period to assess neurodevelopment 
with the ASQ.26 39-41 In addition, children born 
preterm with low scores on the ASQ at 2 years of age, 
but without neurodevelopmental impairment, have 
statistically lower Bayley Scales of Infant Development 
scores compared with children with ASQ scores above 
threshold,40 and, more recently, the predictive value of 
ASQ at 3 years for IQ at 5-6 years has been described.42 
Nevertheless, assessing neurodevelopment at 2 
years, compared with later school age outcomes, is 
challenging as a child’s development does not have 
a fixed trajectory and some children will recover from 
developmental delay while for others their deficit will 
become apparent as they grow.43 44 Children identified 
early using parental questionnaires might benefit 
from closer follow-up and a standardised evaluation 
with formal psychometric tests. Our data offer real 
life estimates, at a national level, of the number of 
children in each gestational age grouping who may 
need to be included in formal follow-up using parental 
questionnaires to assess development. As expected, 
parents who did not complete the questionnaire or 
completed the questionnaire outside the expected 
age range were of a lower socioeconomic status, and 
thus may need additional support when assessing 
development with a parental questionnaire. The 
decline in the rates of cerebral palsy that we observed 
is consistent with those of cerebral palsy registers 
describing a decreased prevalence of cerebral palsy 
over time, and a substantial reduction in the most 
severe forms, especially in very low and moderately 
low birthweight neonates.45-47 As for other cohorts 
based on gestational age,5 we did not find a reduction 
in the most severe forms (data not shown), but the 
number of children with severe cerebral palsy was too 
small to observe such a difference. Rates of sensory 
impairments were very low but reporting sensory 
outcomes at extremely low gestation is essential 
because impairment increases with age. In the 
EXPRESS cohort, the frequencies of blindness and 
visual impairment increased between 30 months’ 
corrected age6 and 6.5 years,48 with children born 
before 25 weeks’ gestation showing the highest risk of 
visual problems.
Comparison with other studies
The improvements in survival and neurodevelopmental 
outcomes that we observed may reflect advances 
in implementation of evidence based practices 
in obstetric and neonatal care. We observed an 
increase in the use of antenatal corticosteroids and 
surfactant, together with a decline in the postnatal 
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use of steroids, associated with a decrease in severe 
neonatal morbidities. Our results provide additional 
evidence for the effectiveness of strategies adopted 
in the perinatal period, although the respective role 
of each strategy is unknown.49 However, in France, 
compared with countries with active resuscitation for 
periviable neonates,56 15 50 only one infant born at 22-
23 weeks’ gestation survived, and rates of survival and 
survival without neuromotor or sensory disabilities 
were poor for children born at 24 weeks’ gestation, 
with no noticeable improvement between 1997 and 
2011 in either practices or outcomes. As expected from 
the French recommendations,51 52 we have previously 
reported that intensive care was withheld or withdrawn 
in the delivery room for 92.6% of neonates born at 22-
23 weeks’ gestation,53 with provision of comfort care 
until death for those born alive.54 In The Netherlands, 
where perinatal care at extremely low gestation is 
comparable to that in France, the proportion of children 
with severe or moderate disabilities at 2 years was 
higher than those we report from France but included 
children with cognitive impairments.17 The impact of 
active treatment at 22-23 weeks’ gestation on outcomes 
at 24 weeks’ gestation and thereafter is a real question. 
One hypothesis is that if you provide active care at 
22-23 weeks’ gestation, outcomes at 24-26 weeks’ 
gestation improve. Marked differences in hospital 
practices regarding the initiation of active treatment 
in infants born at 22, 23, or 24 weeks’ gestation were 
observed in a sample of units in the USA, with hospital 
rates of active treatment accounting for nearly 80% 
of the between-hospital variation in survival without 
severe impairment among children born at 22 or 23 
weeks, but this relation was attenuated among those 
born at 24 weeks.55 In another paper, the same group 
suggested that centres with higher rates of antenatal 
corticosteroids at 22-24 weeks had reduced rates of 
death and neurodevelopmental impairment among 
children born at higher gestational age.56 We report a 
6.9% rate of cerebral palsy at 24-26 weeks’ gestation, 
with similar proportions at 24 and 25 weeks’ gestation 
and a statistically significant decrease at 26 weeks’ 
gestation. Comparisons with other cohorts are difficult 
as rates were reported for 22-26 weeks’ gestation and 
not by individual weeks of gestation. Reported rates 
of cerebral palsy in surviving infants born at 22-26 
weeks’ gestation vary from 7% in Sweden6 to 10% 
in Australia8 and 14% in England.5 Further research 
is needed to better understand the role of different 
strategies of care on outcomes of extremely premature 
neonates57 and the influence of key practices for 
periviable births that might improve outcomes in more 
mature neonates.56
The proportion of children with ASQ scores below 
threshold may appear high in our cohort. On the basis 
of ASQ reference values,24 12% to 17% of children from 
the general population are considered to need further 
evaluation in at least one developmental domain at 2 
years.24 58 Higher proportions have been found at the 
same age in children born preterm: 41% of those born 
before 28 weeks’ gestation in a Dutch hospital based 
cohort40 and 46% in a French regional based cohort 
of children born at less than 32 weeks’ gestation.26 
As a screening instrument, ASQ identifies more 
children at risk of developmental delay than those 
with a diagnosis based on professionally administered 
psychometric tests.40 The risk of potential over-
identification has been widely debated, but children 
with suspected delay may represent a group at risk 
for future academic difficulties and who could require 
dedicated support systems.59 In each gestational 
age group, communication was the domain most 
frequently scoring below threshold, with proportions 
that were still 17.8% at 32-34 weeks’ gestation. Delay 
in language development, together with poorer social-
emotional competence, was also recently described 
in an Australian cohort of children born between 
32 and 36 weeks,60 and stability of poor language 
performance from 20 months to 8 years of age has been 
shown to be greater for preterm children than for term 
children.61 Given the high prevalence of births after 31 
weeks’ gestation, early identification of children at risk 
of later difficulties to provide targeted interventions 
may have a broad impact on learning disabilities. 
We have shown that parents’ socioeconomic status 
and small for gestational age were the main factors 
associated with ASQ scores below threshold, and 
these should be considered when planning follow-
up. Few interventions have been shown to have a long 
term impact on cognitive outcome, but the impact on 
parents’ wellbeing merits consideration.2262 Compared 
with children born at 27-31 or 32-34 weeks’ gestation, 
a higher proportion of children born at 24-26 weeks’ 
gestation showed ASQ scores below threshold in the 
gross motor domain. Most children failed the most 
complex gross motor items: “jump with both feet” 
(“not yet”=93%) and “kicking a ball” (“not yet” or 
“sometimes”=78%) (data not shown). It is likely 
that some of these children will be identified later as 
children with developmental coordination disorders.31
Context of the study
This study evaluated outcomes at 2 years corrected 
age in a large group of preterm babies, born at 22-34 
weeks’ gestation. French practices do not differ greatly 
from those in many other European countries, and our 
results may be applicable elsewhere.57 The proportion 
of infants at risk of developmental delay was high, even 
for those born at 32-34 weeks’ gestation, which raises 
the question of including these children in follow-up. 
This might have a great implication in terms of cost and 
the size of the workforce required, but individualising 
follow-up according to risk factors other than 
gestational age, together with the use of tools easily 
used in community services, should be considered. 
Parental questionnaires are increasingly popular: they 
can be used at the community level to identify children 
needing further assessment, and decrease the cost of 
medical expenditure. Further follow-up of our study 
sample is in progress and will enable us to examine 
whether ASQ scores below threshold are predictors of 
later difficulties at 5 years.
RESEARCH
the bmj | BMJ 2017;358:j3448 | doi: 10.1136/bmj.j3448 11
The EPIPAGE-2 cohort study provides an extensive 
description of practices around birth at extremely low 
gestation,25354 in a country where active perinatal 
intervention is not currently recommended.51 52 For 
infants born at extremely low gestation, a consistent 
concern in the literature is that increased survival 
may come at the expense of increased long term 
sequelae,63 although recent studies counter this 
notion.5615 A 2010 European survey exploring national 
guidelines of resuscitation for infants born at 22-25 
weeks’ gestation found little consensus on how care 
is managed.64 As in seven other European countries, 
France favoured non-intervention for infants born 
before 24 weeks’ gestation,64 with provision of comfort 
care until death for those born alive.54 Our results 
invite questioning perinatal strategies in France, and 
in countries with similar recommendations. However, 
improving outcomes at extremely low gestational age 
requires a complex change in philosophy of care and 
close cooperation not only between obstetricians and 
neonatologists, but also developmental specialists, 
parent associations, and policy makers. Efficient 
regionalised referral systems and antenatal steroids 
are usually the main focus of intervention advocated 
to improve outcome,65 but countries reporting better 
outcomes also differ in quality of family centred care 
and the organisation of follow-up.67
Conclusion
In this national population based cohort of preterm 
neonates, we showed improvements in survival at 2 years 
without neuromotor disabilities in each gestational age 
group between 1997 and 2011. There was a statistically 
important decrease in the rate of cerebral palsy but the 
risk of developmental delay was high, even in children 
born moderately preterm. Parental questionnaires may 
represent a promising alternative for early identification 
of children at risk of later difficulties.
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